Actinium Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATNM research report →
About the company
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT.
- CEO
- Sandesh C. Seth
- IPO
- 2012
- Employees
- 31
- HQ
- New York City, NY, US
Price Chart
- Market Cap
- $30.78M
- P/E
- -1.31
- P/S
- 341.99
- P/B
- 13.30
- EV/EBITDA
- 0.43
- Div Yield
- 0.00%
- Gross Margin
- 538.89%
- Op Margin
- -28346.67%
- Net Margin
- -26078.89%
- ROE
- -218.67%
- ROIC
- -65.71%
- Revenue
- $90.00K · 0.00%
- Net Income
- $-33,887,000 · 11.39%
- EPS
- $-1.09 · 14.17%
- Op Income
- $-36,247,000
- FCF YoY
- 25.39%
- 52W High
- $1.89
- 52W Low
- $0.94
- 50D MA
- $1.14
- 200D MA
- $1.29
- Beta
- -0.01
- Avg Volume
- 180.44K
Get TickerSpark's AI analysis on ATNM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 18, 25 | SETH SANDESH | other | 120,900 |
| Mar 31, 25 | Steinhart Richard I | sell | 72,156 |
| Mar 31, 25 | Steinhart Richard I | sell | 8,333 |
| Mar 31, 25 | Steinhart Richard I | sell | 2,500 |
| Mar 31, 25 | Steinhart Richard I | sell | 2,500 |
| Mar 31, 25 | Steinhart Richard I | sell | 70,311 |
| Mar 31, 25 | Steinhart Richard I | sell | 18,351 |
| Mar 31, 25 | Steinhart Richard I | sell | 8,333 |
| Mar 31, 25 | Steinhart Richard I | sell | 2,500 |
| Mar 31, 25 | Chell Jeffrey W. | sell | 2,500 |
Our ATNM coverage
Recent articles, reports, and earnings notes.
No research on ATNM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ATNM report →Similar companies
Peers in the same neighborhood.